Advertisement

Clinical and Translational Oncology

, Volume 16, Issue 3, pp 273–279 | Cite as

Should we continue temozolomide beyond six cycles in the adjuvant treatment of glioblastoma without an evidence of clinical benefit? A cost analysis based on prescribing patterns in Spain

  • C. BalañáEmail author
  • M. A. Vaz
  • D. Lopez
  • R. de la Peñas
  • J. M. García-Bueno
  • M. J. Molina-Garrido
  • J. M. Sepúlveda
  • J. M. Cano
  • C. Bugés
  • S. M. Sanz
  • J. L. Arranz
  • P. Perez-Segura
  • A. Rodriguez
  • J. M. Martin
  • M. Benavides
  • M. Gil
Research Article

Abstract

Purpose

The standard adjuvant treatment for glioblastoma is temozolomide concomitant with radiotherapy, followed by a further six cycles of temozolomide. However, due to the lack of empirical evidence and international consensus regarding the optimal duration of temozolomide treatment, it is often extended to 12 or more cycles, even in the absence of residual disease. No clinical trial has shown clear evidence of clinical benefit of this extended treatment. We have explored the economic impact of this practice in Spain.

Materials and methods

Spanish neuro-oncologists completed a questionnaire on the clinical management of glioblastomas in their centers. Based on their responses and on available clinical and demographic data, we estimated the number of patients who receive more than six cycles of temozolomide and calculated the cost of this extended treatment.

Results

Temozolomide treatment is continued for more than six cycles by 80.5 % of neuro-oncologists: 44.4 % only if there is residual disease; 27.8 % for 12 cycles even in the absence of residual disease; and 8.3 % until progression. Thus, 292 patients annually will continue treatment beyond six cycles in spite of a lack of clear evidence of clinical benefit. Temozolomide is covered by the National Health Insurance System, and the additional economic burden to society of this extended treatment is nearly 1.5 million euros a year.

Conclusions

The optimal duration of adjuvant temozolomide treatment merits investigation in a clinical trial due to the economic consequences of prolonged treatment without evidence of greater patient benefit.

Keywords

Extended adjuvant treatment Glioblastoma Pharmacoeconomics Pseudoprogression Residual disease Temozolomide 

Notes

Acknowledgments

The authors would like to thank the following neuro-oncologists who participated in the survey: V. Moreno (Hospital La Paz, Madrid), O. Gallego (Hospital Sant Pau, Barcelona), C. Sanchez (Hospital Virgen de las Nieves, Granada), I. Marquez (Hospital Gregorio Marañón, Madrid), I. Fernandez (Hospital Universitario, Vigo), P. Fuster (Hospital Son Espases, Palma de Mallorca), E. Pujol (Hospital Lozano Blesa, Zaragoza), M. Navarro (Hospital Universitario, Salamanca), C. Mesía (Catalan Institute of Oncology, Hospital Duran i Reynals, Hospitalet de Llobregat, Barcelona), T. Quejereta (Hospital Infanta Cristina, Badajoz), S. Del Barco (Catalan Institute of Oncology, Hospital Trueta, Girona), C. Olier (Hospital de Alcorcón, Madrid), P. Ramirez (Hospital Puerta de Cádiz, Cádiz), E. Vicente (Hospital Insular de Gran Canaria, Las Palmas), R. Marsé (Hospital Son Espases, Palma de Mallorca), S. Peralta (Hospital Sant Joan, Reus), M. Santiesteban (Clinica de Navarra, Navarra), T. Quintanar (Hospital Universitario de Elche, Elche), A. Herrero (Hospital Miquel Servet, Zaragoza), M. Quindos (Hospital Teresa Herrera, Complejo Hospitalario La Coruña, La Coruña), B. Perez-Valderrama (Hospital Virgen del Rocio, Sevilla), R. Romero (Hospital Lucus Agusti, Lugo). The authors also thank Mercè Francisco and Anna del Prado from Marketing Farmacéutico & Investigación Clínica, S.L. (MFAR) for their expert technical assistance in conducting the survey and Renée O’Brate for her assistance in drafting the manuscript. This work has received no financial support.

Conflict of interest

The authors have declared no conflicts of interest.

References

  1. 1.
    Crocetti E, Trama A, Stiller C, Caldarella A, Soffietti R, Jaal J, et al. Epidemiology of glial and non-glial brain tumours in Europe. Eur J Cancer. 2012;48:1532–42.PubMedCrossRefGoogle Scholar
  2. 2.
    Dolecek TA, Propp JM, Stroup NE, Kruchko C. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005–2009. Neuro Oncol. 2012;14(Suppl 5):v1–49.PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Fuentes-Raspall R, Vilardell L, Perez-Bueno F, Joly C, Garcia-Gil M, Garcia-Velasco A, et al. Population-based incidence and survival of central nervous system (CNS) malignancies in Girona (Spain) 1994–2005. J Neurooncol. 2011;101:117–23.PubMedCrossRefGoogle Scholar
  4. 4.
    Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC–NCIC trial. Lancet Oncol. 2009;10:459–66.PubMedCrossRefGoogle Scholar
  5. 5.
    Malkoun N, Chargari C, Forest F, Fotso MJ, Cartier L, Auberdiac P, et al. Prolonged temozolomide for treatment of glioblastoma: preliminary clinical results and prognostic value of p53 overexpression. J Neurooncol. 2012;106:127–33.PubMedCrossRefGoogle Scholar
  6. 6.
    Roldan Urgoiti GB, Singh AD, Easaw JC. Extended adjuvant temozolomide for treatment of newly diagnosed glioblastoma multiforme. J Neurooncol. 2012;108:173–7.PubMedCrossRefGoogle Scholar
  7. 7.
    Groves MD Jr, Plummer AB. Helping patients make the best decision regarding duration of temozolomide chemotherapy treatment. Continuum (Minneap Minn). 2012;18:421–5.Google Scholar
  8. 8.
    Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent MJ. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol. 2008;9:453–61.PubMedCrossRefGoogle Scholar
  9. 9.
    Brandes AA, Franceschi E, Tosoni A, Blatt V, Pession A, Tallini G, et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol. 2008;26:2192–7.PubMedCrossRefGoogle Scholar
  10. 10.
    Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997–1003.PubMedCrossRefGoogle Scholar
  11. 11.
    Brandes AA, Tosoni A, Spagnolli F, Frezza G, Leonardi M, Calbucci F, et al. Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: pitfalls in neurooncology. Neuro Oncol. 2008;10:361–7.PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Graus F, Bruna J, Pardo J, Escudero D, Vilas D, Barcelo I et al. Patterns of care and outcome for patients with glioblastoma diagnosed during 2008–2010 in Spain. Neuro Oncol. 2013;15(6):797–805.Google Scholar
  13. 13.
    Bauchet L, Mathieu-Daude H, Fabbro-Peray P, Rigau V, Fabbro M, Chinot O, et al. Oncological patterns of care and outcome for 952 patients with newly diagnosed glioblastoma in 2004. Neuro Oncol. 2010;12:725–35.PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    Brada M, Hoang-Xuan K, Rampling R, Dietrich PY, Dirix LY, Macdonald D, et al. Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol. 2001;12:259–66.PubMedCrossRefGoogle Scholar
  15. 15.
    Yung WK, Albright RE, Olson J, Fredericks R, Fink K, Prados MD, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer. 2000;83:588–93.PubMedCentralPubMedCrossRefGoogle Scholar
  16. 16.
    Stupp R, Tonn JC, Brada M, Pentheroudakis G. High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(Suppl 5):v190–3.PubMedCrossRefGoogle Scholar
  17. 17.
    Mason WP, Maestro RD, Eisenstat D, Forsyth P, Fulton D, Laperriere N, et al. Canadian recommendations for the treatment of glioblastoma multiforme. Curr Oncol. 2007;14:110–7.PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    Malkoun N, Fotso MJ, Cartier L, Forest F, Auberdiac P, Chargari C, et al. Benefit of a prolonged adjuvant treatment with temozolomide for the management of patients with glioblastoma. Cancer Radiother. 2011;15:202–7.PubMedCrossRefGoogle Scholar
  19. 19.
    Grossman SA, Ye X, Piantadosi S, Desideri S, Nabors LB, Rosenfeld M, et al. Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. Clin Cancer Res. 2010;16:2443–9.PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    American Society of Clinical Oncology. RTOG 0525: A randomized phase III trial comparing standard adjuvant temozolomide (TMZ) with a dose-dense (dd) schedule in newly diagnosed glioblastoma (GBM). In: Gilbert MR, Wang M, Aldape KD, Stupp R, Hegi M, Jaeckle KA et al, editors. Proceedings of the 2011 ASCO Meeting. June 3–7. Chicago, USA.Google Scholar
  21. 21.
    Weller M, Stupp R, Reifenberger G, Brandes AA, van den Bent MJ, Wick W, et al. MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat Rev Neurol. 2010;6:39–51.PubMedCrossRefGoogle Scholar
  22. 22.
    Holdhoff M, Grossman SA. Controversies in the adjuvant therapy of high-grade gliomas. Oncologist. 2011;16:351–8.PubMedCrossRefGoogle Scholar
  23. 23.
    Franceschi E, Tosoni A, Brandes AA. Adjuvant temozolomide: how long and how much? Expert Rev Anticancer Ther. 2008;8:663–5.PubMedCrossRefGoogle Scholar

Copyright information

© Federación de Sociedades Españolas de Oncología (FESEO) 2013

Authors and Affiliations

  • C. Balañá
    • 1
    Email author
  • M. A. Vaz
    • 2
  • D. Lopez
    • 3
  • R. de la Peñas
    • 4
  • J. M. García-Bueno
    • 5
  • M. J. Molina-Garrido
    • 6
  • J. M. Sepúlveda
    • 7
  • J. M. Cano
    • 8
  • C. Bugés
    • 1
  • S. M. Sanz
    • 9
  • J. L. Arranz
    • 10
  • P. Perez-Segura
    • 11
  • A. Rodriguez
    • 12
  • J. M. Martin
    • 13
  • M. Benavides
    • 14
  • M. Gil
    • 15
  1. 1.Medical Oncology ServiceCatalan Institute of Oncology, Hospital Germans Trias i PujolBadalonaSpain
  2. 2.Medical Oncology ServiceHospital Ramón y CajalMadridSpain
  3. 3.Pharmacy ServiceCatalan Institute of Oncology, Hospital Germans Trias i PujolBadalonaSpain
  4. 4.Medical Oncology ServiceHospital Provincial de CastellónCastellónSpain
  5. 5.Medical Oncology ServiceHospital General de AlbaceteAlbaceteSpain
  6. 6.Medical Oncology ServiceHospital General Virgen de la LuzCuencaSpain
  7. 7.Medical Oncology ServiceHospital 12 de OctubreMadridSpain
  8. 8.Medical Oncology ServiceHospital General de Ciudad RealCiudad RealSpain
  9. 9.Medical Oncology ServiceHospital Arnau de VilanovaLleidaSpain
  10. 10.Medical Oncology ServiceFundación Jimenez DiazMadridSpain
  11. 11.Medical Oncology ServiceHospital Clínico San CarlosMadridSpain
  12. 12.Medical Oncology ServiceHospital de LeónLeonSpain
  13. 13.Medical Oncology ServiceHospital de GetafeMadridSpain
  14. 14.Medical Oncology ServiceHospital Regional Carlos HayaMalagaSpain
  15. 15.Medical Oncology ServiceInstitut de Recerca Biomèdica de Bellvitge (IDIBELL) and Catalan Institute of Oncology, Hospital Duran ReynalsL’Hospitalet de Llobregat, BarcelonaSpain

Personalised recommendations